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Abstract
Purpose Use of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of blad-
der cancer biology which may help identify disease earlier, risk stratify patients, improve prediction of outcomes or help 
target therapy.
Methods A review of the published literature was performed, without restriction of time.
Results Despite the fast-growing literature about the topic and the approval of several urinary biomarkers for use in clinical 
practice, they have not reached the level of evidence for widespread utilization. Biomarkers could be used in different clini-
cal scenarios, mainly to overcome the limitations of current diagnostic, predictive, and prognostic tools. They have been 
evaluated to detect bladder cancer in asymptomatic populations or those with hematuria and in surveillance of disease as 
adjuncts to cystoscopy. There is also a potential role as prognosticators of disease recurrence, progression and survival both 
in patients with non-invasive cancers and in those with advanced disease. Finally, they promise to be helpful in predicting 
the response to local and/or systemic chemotherapy and/or immunotherapy.
Conclusions To date, due to the lack of high-quality prospective trials, the level of evidence provided by the current literature 
remains low and, therefore, the potential of biomarkers exceeds utilization in clinical practice.
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Introduction
Bladder cancer (BCa) is a heterogeneous disease with sig-
nificant diagnostic, therapeutic and prognostic challenges 
[1]. The tools available to clinicians for diagnosis and stag-
ing require invasive procedures such as cystoscopy and 
biopsy in addition to imaging with computer tomography 
and magnetic resonance. These tools, however, often under-
stage patients and lack sensitivity to detect all cancers (false 
negatives) and specifically micro-metastatic disease. These 
imprecisions in capturing the clinical and biologic poten-
tials of a tumor result in over- and under-treatment with side 
effects of therapies [2].
Molecular markers detected in urine, tissue or blood offer 
promising opportunities to improve our understanding of 
biology of a specific cancer and its micro- and macroen-
vironment. This could help identify disease earlier, risk 
stratify patients, improve prognostication and prediction of 
outcomes and help target therapy. While some areas such as 
urine-based tumor markers have been more extensively stud-
ied, the current guidelines have yet to embrace markers in 
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routine management of BCa [3]. In this consensus guideline, 
part of the SIU–ICUD update on BCa, we review the chal-
lenges of introducing markers into clinical care and discuss 
urine-, tissue- and blood-based markers for different stages 
of disease and different clinical scenarios. Evidence was 
selected through a non-systematic review of the literature.
Challenges of marker introduction 
into clinical practice
Biomarker research can be categorized, similar to drug-
development studies, into initial pre-clinical exploratory 
studies, clinical assay development and validation studies, 
small clinical retrospective studies, external validation in 
larger cohorts (retrospective or prospective, usually multi-
institutional), prospective clinical trials and further post-
approval studies as well as possible expansion to other 
clinical scenarios and disease stages [4, 5]. In an attempt to 
improve design, analysis and reporting of marker studies, a 
set of reporting recommendations has been developed and 
is generally accepted.
The main goal for marker development is to identify a 
validated test which can improve clinical decision-making in 
a cost-effective way. It is, therefore, not sufficient to merely 
show statistically significant independent association of the 
marker with the investigated outcome, but to show improved 
prognostic or predictive accuracy of a multivariable model 
over already available clinical features alone. Ideally, the 
integration of the marker should be improved with regard to 
discrimination, calibration and decision-analysis [5].
Finally, BCa is a heterogeneous disease. Therefore, it is 
unlikely that one single marker exists that can adequately 
characterize the potential and behavior of a cancer to allow 
reliable treatment conclusions. This has led many investiga-
tors to evaluate comprehensive pathways rather than single 
markers [6, 7]. Marker panels including drivers from key 
pathways in combination with clinical and pathological vari-
ables might be the most promising approach for accurate risk 
stratification and clinical decision-making for BCa.
Biomarkers according to clinical stages
Urinary biomarkers for screening and hematuria 
workup
In patients without history of BCa, there are several sce-
narios in which urinary biomarkers may play a role. One 
scenario that has frequently been discussed is the use of bio-
markers for screening purposes. So far, the low prevalence of 
the disease in the general population has been a challenge for 
developing effective screening strategies [8]. Actually, the 
effectiveness of a screening program is significantly affected 
by the incidence and mortality of a specific disease. The 
number of trials applying biomarkers for BCa in a screening 
population is limited and, to date, there are no randomized 
controlled trials.
Identification of high-risk populations may help over-
come these limitations [9]. However, data from recent trials 
indicate that even in patients with an increased risk of devel-
oping BCa such as workers exposed to occupational hazards 
with carcinogenic potential or heavy smokers, the incidence 
of BCa is too low for a broad screening to have a socioeco-
nomic benefit. Lotan et al. [10], for example, assessed the 
value of NMP22 in a high-risk population including 1175 
men and 327 women based on a history of at least 10 years 
of smoking or an occupational exposure of at least 15 years. 
Eighty-five (5.7%) subjects had a positive NMP-22. Three 
from the 69 patients undergoing further evaluation had 
abnormal findings (one pTa low-grade tumor, one pTa high-
grade tumor and one atypia). During long-term follow-up, 
only nine additional patients were diagnosed with BCa [11]. 
Of note, no patient had muscle-invasive cancer (MIBC) and 
a positive NMP22 was not associated with worse overall 
survival (OS).
A second clinical scenario in which urinary biomarkers 
may add value is in the risk stratifying patients with asymp-
tomatic microhematuria (AMH). Patients with asymptomatic 
gross hematuria have a significant risk of BCa (approxi-
mately 10%) making urologic workup necessary [12]. 
In these patients, urinary biomarkers could be used as an 
adjunct to cystoscopy and imaging but are currently unlikely 
to impact the diagnostic strategies. In patients with AMH, 
international guidelines differ significantly on the optimal 
workup. The prevalence of AMH in the adult population 
ranges as high as 18%, yet only 2% of the referred patients 
harbor BCa. This has led to a nonchalant general approach to 
AMH with limited workups and delayed referrals resulting 
in late diagnosis, especially in women [13]. In this setting, 
urinary biomarkers may help early identification of patients 
at risk triaging and fastening referral for a urologic workup 
[12, 14–16]. Cha et al. performed a retrospective analysis of 
1182 patients with hematuria, including 68% with AMH and 
evaluated cytology, imaging, cystoscopy, and immunocytol-
ogy in all patients. A nomogram predicting the risk of BCa 
was constructed showing a predictive accuracy of 90.8% 
[17]. Lotan et al. [15] validated a nomogram incorporat-
ing age, gender, ethnicity, smoking history, type of hematu-
ria, cytology and NMP22 BladderChek in a cohort of 381 
subjects with hematuria. In total, 23 patients (6.0%) had 
BCa. The predictive accuracy of the nomogram was 80.2%. 
Finally, in a cohort including 86 patients with AMH and 
83 patients with gross hematuria, Beukert et al. [18] used 
methylation analysis of OSR1, SIM2, OTX1, MEIS1 and 
ONECUT2 for developing a model for prediction of BCa. 
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The model also included clinicopathologic characteristics 
such as type of hematuria, age, gender and cytology results. 
The model yielded a sensitivity and specificity of 85% and 
87% with an area under the curve (AUC) of 89%.
While these studies suggest a potential benefit to urinary 
biomarkers in patients with AMH, prospective controlled tri-
als are lacking and urgently needed. Moreover, so far, there 
is no evidence that the use of urinary biomarkers in a screen-
ing/early detection setting has an effect on cancer-specific 
mortality [3]. Therefore, due to the low levels of evidence 
(LoE) provided, urinary biomarkers are currently not rec-
ommended for the screening of BCa or in prioritization of 
patients with AMH.
Urinary biomarkers in surveillance setting
Urinary biomarkers in surveillance setting have been devel-
oped to overcome the limitations of cystoscopy and urine 
cytology. The former is invasive and may miss significant 
proportion of cancer recurrences, especially CIS, whereas 
the latter has low sensitivity in low-/intermediate-risk non-
muscle-invasive bladder cancer (NMIBC) and suffers from 
considerable inter- and intra-observer variabilities especially 
in patients after BCG immunotherapy [19–21]. Biomarker 
implementation in surveillance may be categorized with two 
potential applications: (1) as an adjunct to cystoscopy and 
(2) its substitute. Furthermore, the role of a biomarker in 
clinical decision-making would be different in low-/inter-
mediate-risk NMIBC and in high-risk NMIBC. In patients 
with low-grade disease it is possible that a marker could 
reduce the number of cystoscopies needed. For high-grade 
cancers, the marker would be an adjunct to cystoscopy and 
an abnormal result would increase awareness of patients and 
physicians, identify those at risk of progression, facilitate 
the interpretation of indeterminate results of cytology and 
assess response to BCG.
A urine marker would need a very high sensitivity and 
negative predictive value (NPV) to replace cystoscopy. One 
recent survey suggests that patient preference would have 
sensitivity as high as 90–95% for a marker to replace cys-
toscopy [22]. Overall, reported sensitivities of voided urine 
cytology, NMP22 (nuclear matrix protein), BTA (bladder 
tumor antigen) stat and BTA trak, Immunocyt, UBC test, 
Cyfra 21-1, FISH (fluorescence in situ hybridization) and 
Cxbladder Monitor in this setting differ widely between 
trials, ranging from 7% to 93% [23, 24]. Similarly, corre-
sponding specificities range from 49% to 99% [25, 26]. Of 
these biomarkers, only Cxbladder Monitor has shown a high 
sensitivity (91–93%) while its rate of false-negative results 
does not exceed 1.5% [24]. Both metrics are believed to be 
prerequisites for the test to supplant cystoscopy. However, 
for low-grade tumors it may be less clinically relevant if a 
small tumor is missed by either cystoscopy or a marker.
Due to the unsatisfactory performances of most single 
biomarkers, panels of markers have been used to improve 
sensitivity or alternatively combining markers. One study 
found that combining two tests among cytology, immu-
nocytology, FISH and NMP22 resulted in sensitivity and 
negative predictive value of no greater than 89.8% (Immu-
nocyt + NMP22) and 92.1% (FISH + Immunocyt) [27]. If 
cytology is supplemented with any of the four tests, cor-
responding values are no greater than 86.7% (NMP22) and 
91.3% (immunocytology). Adding FISH to conventional 
urine cytology is associated with 80.5% sensitivity (94.0% 
for high-risk tumors) and 90.1% negative predictive value 
(98.8% for high-risk tumors).
Based on these findings, the European (EAU), the Ameri-
can Urological Associations (AUA) as well as the Society 
of Urologic Oncology (SUO) do not recommend urinary 
biomarkers yet for the routine surveillance of patients with 
NMIBC [28, 29]. According to AUA/SUO Guideline “clini-
cian may use biomarkers to assess response to intravesical 
BCG (UroVysion® FISH) and adjudicate equivocal cytol-
ogy (UroVysion® FISH and ImmunoCyt®)” [29]. Actually, 
serial measurements of UroVysion FISH in patients sub-
jected to BCG therapy revealed that abnormal test results at 
baseline (before BCG), at 6 weeks (before the  6th BCG instil-
lation) and before the 3 months’ cystoscopy (before the first 
maintenance course) are significantly associated with both 
cancer recurrence and progression. FISH at 3 months iden-
tified 50% of patients who experienced cancer progression 
within 2 years in half of those with positive test compared 
to only 3% of those who had normal result [30].
Another approach toward improving surveillance proto-
cols of NMIBC and optimizing costs is to use reflex testing. 
In patients with negative/uncertain result of one test, the 
accuracy of follow-up is significantly increased by adding 
subsequent highly sensitive biomarkers. Immunotherapy 
is known to evoke inflammatory changes within the blad-
der often making reliable assessment of the lower urinary 
tract challenging. As such, accuracy of cytology used as an 
adjunct to cystoscopy to increase the detection of CIS or 
upper tract lesions is hampered by BCG. FISH and Immu-
noCyt® were investigated in patients with atypical cytol-
ogy. UroVysion FISH has 100% sensitivity and 100% nega-
tive predictive value in those with negative cystoscopy, yet 
equivocal cytology [31]. ImmunoCyt has 73% sensitivity in 
detecting recurrent bladder tumor in patients with atypical 
cytology with corresponding negative predictive value of 
80% [32]. In summary, both tests are recognized by AUA/
SUO as the potential reflex biomarkers to adjudicate atypical 
cytology to help avoid unnecessary workups.
In summary, in the surveillance of patients with NMIBC, 
there is insufficient evidence that urinary biomarkers can 
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replace cystoscopy and prospective studies are necessary to 
demonstrate whether this is safe. Urinary biomarkers, how-
ever, could be used to help assess the response to intravesical 
immunotherapy and as reflex test in cases with equivocal 
urinary cytology (Expert Opinion).
Tissue biomarkers for non‑muscle‑invasive bladder 
cancer
Tissue biomarkers can theoretically be used in NMIBC to 
predict oncological outcomes such as recurrence and pro-
gression as well as the response to intravesical BCG and, 
ideally, could be used to improve individualized treatment 
and surveillance based on individualized risk profiles. 
Moreover, they can be useful to identify the proportion of 
high-risk NMIBC patients who are likely to develop disease 
progression to invasive disease, thus requiring consideration 
for intensified therapy such as early radical cystectomy.
To date biomarkers associated with pathways important 
for tumor growth and spread have been evaluated inten-
sively, such as cycle cell regulators, angiogenesis, apoptosis, 
signaling proteins and hormones.
p53, the product of TP53, the most common oncosup-
pressor gene mutated in all human cancers, has been asso-
ciated with features of tumor aggressiveness and correlated 
with poor oncological outcomes [6, 33–37]. Moreover, it 
is associated with the most aggressive T1G3 cancers. Two 
meta-analyses summarizing the role of p53 in NMIBC 
showed that its overexpression can predict progression in 
T1HG patients but is not able to predict the response to BCG 
therapy [38, 39]. However, the heterogeneity of the included 
studies and limitations related to the immunohistochemistry 
hampered any clear conclusions [38].
The association between an altered expression of the 
tumor suppressor retinoblastoma (Rb) and oncological out-
comes in BCa is relatively weak and the majority of trials 
failed to find an association with recurrence and progression 
[40]. More recently, it has been shown that Rb could be of 
predictive utility for BCa recurrence and progression only 
when combined with other biomarkers such as p53 and p27 
[6, 34] in a panel of markers.
The antiapoptotic biomarker survivin was found to pre-
dict recurrence, progression and survival [41, 42]. In the 
largest series, Fristrup et al. [43] analyzed the expression 
of survivin in 283 NMIBC patients and reported a strong 
association with recurrence, progression and OS. Recently, 
a meta-analysis of 14 studies reported a statistically signifi-
cant association with recurrence, cancer-specific survival 
(CSS), and OS [44]. However, prospective large series are 
lacking. Other biomarkers of apoptosis such as Livin, Bcl-2 
and Bax have been investigated, but there are few studies 
[45, 46]. Finally, cell signaling pathway biomarkers such as 
ErbB and FGFR family members as well as angiogenesis 
(VEGF, MVD, HIF-1α) and tumor cell invasion biomarkers 
(E-cadherin and N-cadherin) have been shown to be related 
to outcomes of NMIBC [47, 48].
Based on the current literature, one can conclude that 
none of the evaluated tissue biomarkers alone could be used 
to predict oncological outcomes with sufficient accuracy to 
change decisions in routine clinical practice. Therefore, it 
has been postulated that a panel of biomarkers could improve 
the predictive accuracy over clinical information alone [49, 
50]. However, even in this setting, results are conflicting and, 
therefore, to date, due to the low level of evidence and to the 
contrasting reported findings, the use of tissue biomarkers in 
BCa is not recommended since it does not change/improve 
clinical decision-making.
Blood and tissue biomarkers for invasive bladder 
cancer
Tissue‑based biomarkers
The development of MIBC involves alterations in multiple 
homeostatic pathways with profound deregulations within a 
complex molecular circuitry. Therefore, these alterations can 
serve as prognosticators of outcomes, predictors of response 
to therapy, and they may also act as therapeutic targets.
Several retrospective studies have reported that nuclear 
accumulation of p53 is prognostic in MIBC, especially in 
patients treated with radical cystectomy [51, 52]. However, 
at this time, the use of p53 as a prognostic biomarker in 
MIBC is still not clinically established despite over 100 stud-
ies evaluating its utility. Actually, a phase III trial designed 
to evaluate the benefit of stratifying organ-confined invasive 
BCa patients based on their p53 status for adjuvant cisplatin-
based chemotherapy could not confirm the prognostic value 
of the p53 alteration [53].
Inactivating mutation of Rb, in conjunction with other 
cell cycle regulatory proteins, has been shown to be prognos-
tic in MIBC [54]. Combined immunohistochemical assess-
ment of p53, p21, Rb, cyclin E1 and p27 has been shown 
to yield predictive accuracies superior to that of any single 
biomarker in patients with BCa treated with radical cys-
tectomy, and improving risk stratification by a significant 
prognostic margin [55–57].
As in NMIBC, apoptosis biomarkers such as survivin 
and Bcl-2 family are associated with outcomes in MIBC 
[7]. Interestingly, the proportion of specimens with sur-
vivin overexpression increases progressively from NMIBC 
to MIBC and to metastatic lymph node tissue [41]. In a 
large multicenter international validation study, addition 
of survivin significantly improved the accuracy of standard 
clinicopathologic features for prediction of disease recur-
rence and CSS in a subgroup of patients with pT1-3N0M0 
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disease [58]. Proliferation and angiogenesis biomarkers such 
as Ki67, VEGF and microvessel density have been associ-
ated with higher pathologic stage, lymphovascular invasion, 
lymph node metastasis, disease recurrence and CSS [59–62].
Finally, tissue-based gene- and transcriptome-level profil-
ing has been used to identify biomarkers that characterize 
and can potentially predict prognosis in patients with MIBC 
[63]. Comprehensive characterization of the genomic land-
scape of BCa through efforts of The Cancer Genome Atlas 
Research Network resulted in identification of four expres-
sion clusters of high-grade MIBC [64]. Tumors in cluster 
I had papillary-like morphology with increased FGFR3 
expression, mutations and copy number gain, thereby sug-
gesting that these patients may respond to FGFR inhibi-
tors or its downstream targets. These tumors also showed 
decreased miR-99a and miR-100 expressions, which in turn 
downregulate FGFR3 expression [65]. Tumors in clusters 
I and II have similar features to those of luminal A breast 
cancer, with high expression of luminal breast differentia-
tion markers, including GATA3 and FOXA1. These tumors 
also harbor increased expression of uroplakins, E-cadherin 
and members of the miR-200 family. Increased expression 
of ERBB2 and estrogen receptor-β by these tumors also sug-
gested that they may serve as potential targets for hormo-
nal therapies. Expression signature of tumors in cluster III 
(‘basal/squamous-like’) were similar to that of basal-like 
breast cancers and squamous cell cancers of the head and 
neck and lung, characterized by overexpression of epithe-
lial lineage genes. These findings suggest the presence of 
distinct molecular subtypes of MIBC with characteristic 
expression signatures, which may impact prognosis and 
serve as candidates for selective therapeutic strategies [66].
Blood‑based biomarkers
Assessment of biomarkers in blood offers several advantages 
over tissue samples, such as ease of procurement, minimally 
invasive collection method, and higher sample homogeneity. 
However, clinical applicability and value of these biomark-
ers in the setting of MIBC remain to be further tested and 
validated in large well-controlled multi-institutional studies.
Biomarkers associated with cellular proliferation such 
as insulin growth factor binding proteins (IGFBPs) play a 
central role in regulating cellular growth, proliferation and 
transformation. IGFBP-3 is a member of this family that also 
has its own pro-apoptotic effects. Lower preoperative plasma 
levels of IGFBP-3 are a significant predictor of lymph node 
involvement in patients undergoing radical cystectomy and 
also portended a significantly increased risk of disease recur-
rence and cancer-specific mortality [67]. Similarly, elevated 
preoperative plasma levels of transforming growth factor–β1 
(TGF-β1) protein have been associated with lymphovascular 
invasion, nodal and distant metastasis, disease recurrence 
and CSS [68, 69].
Inflammation and immune biomarkers such as interleu-
kin-6 and C-reactive protein (the most widely studied serum 
marker for inflammation in BCa) have been consistently 
associated with adverse survival outcomes [70–72]. In line 
with observations, elevated serum levels of VEGF have also 
been associated with high stage and grade, lymphovascular 
invasion, metastases, and poor CSS [73].
The presence of circulating tumor cells (CTCs) in periph-
eral blood may represent an early step in the metastatic pro-
gression of BCa. In an evaluation of 55 patients undergoing 
radical cystectomy, the presence of CTCs was associated 
with survival. The study noted that patients with one or 
more CTCs had a shorter time to disease recurrence and 
shorter CSS than those with none [74]. These findings were 
are also found in a larger cohort of 100 consecutive patients 
with non-metastatic BCa undergoing radical cystectomy 
[75].However, despite these encouraging results, the use 
of blood- and tissue-based biomarkers for prediction and 
guidance of clinical decision-making in MIBC is still too 
immature due to the weak strength of evidence of published 




In BCa, chemotherapy can be administered intravesically 
(usually for NMIBC) or systemically (for MIBC and meta-
static BCa). Prediction of response to chemotherapies could 
be helpful for decision regarding type and timing of systemic 
and local therapies.
A hallmark of cancer, including BCa, is dysregulation of 
the cell cycle which results in the sustained signal for prolif-
eration required for cancer development. Several cell cycle 
regulators and markers of proliferation have been tested as 
predictors of chemotherapy response such as CyclinD1, 
CCDN1 and Ki-67. A second hallmark of cancers is their 
ability to escape apoptosis, a process controlled by cas-
pases. Caspases, in turn, are regulated by several molecules 
involved in the detection of DNA or mitochondrial damage, 
including p53 and Bcl-2. p53 has been extensively tested in 
BCa, both as a prognostic biomarker and as a predictor of 
treatment response. While initial retrospective studies were 
promising, randomized trial results showed no role for p53 
as a predictor of chemotherapy response [53, 76].
Many chemotherapy agents work by causing DNA dam-
age and, if its DNA integrity is sufficiently disrupted, the 
cancer cell cannot replicate. Cancer cells that have defi-
cient DNA damage repair mechanisms are unable to fix 
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the damage induced by these chemotherapy agents and are, 
therefore, more susceptible to being killed by the agents. 
Proteins involved in DNA damage detection and repair that 
play a role in BCa chemotherapy response include BRCA-1, 
BRCA-2, RAD51, PARP1, ERCC1, ERCC2, ATM, RB1, 
and FANCC. In the study by Plimack et al., response to 
neoadjuvant chemotherapy (NAC) before radical cystectomy 
(stage T1 or less at surgery) was associated with an altera-
tion in ATM, RB1 or FANCC [77]. Similarly, in a validation 
study on the role of ERCC2, ERCC2 mutation was present in 
80% of patients who had pathologic stage T1 or less at time 
of radical cystectomy after NAC (i.e., responders) [78, 79].
It has been known for decades that the mitogenic signals 
derived from the binding of growth factors to their receptors 
are crucial for cancer development. Many growth factors 
and growth factor receptors signal into the cell via trans-
membrane tyrosine kinases, and these kinases are the tar-
gets of several new systemic therapies in oncology (such as 
lapatinib, pazopanib, and sunitinib). While these three drugs 
appear to have limited activity in BCa, the possibility of 
biomarker enrichment for response has been assessed [80]. 
Finally, microRNAs’ expression, germline single nucleotide 
polymorphisms, DNA ploidy, S-phase fraction (a prolifera-
tive index) and immune markers such as lymphocyte count 
and interleukin-8 have been preliminarily tested as predic-
tors of chemotherapy response.
Based on the current data, none of the biomarkers has 
reached the level of evidence sufficient to determine thera-
peutic approach and resistance to targeted chemotherapies. 
Ongoing, biomarker-driven trials will shine more light on 
this important issue.
Response to systemic immunotherapy
Over the last years, immunotherapies have proven unprec-
edented activity in BCa after failure of cisplatin-based ther-
apies or in patients not suitable to receive cisplatin-based 
chemotherapy. Inhibition of immune checkpoints has been 
shown for several agents targeting programmed death-1 
(PD-1) receptor or its ligand (PD-L1) and cytotoxic T-lym-
phocyte antigen 4 (CTLA-4). Nevertheless, the majority of 
patients still do not respond to treatment [81–88], which 
results in a significant financial burden and potential treat-
ment-related side effects to patients who do not benefit from 
therapy. Therefore, biomarkers are needed to predict those 
most likely to benefit from checkpoint targeting therapy.
The expression of T-cell coregulatory proteins is altered 
in a large proportion of BCa with differential upregulation 
in cancer versus normal urothelium, and an association of 
B7-H1 with mortality after radical cystectomy in organ-
confined disease has been shown [89]. Detection of PD-L1 
on tumor samples with immunohistochemistry (IHC) has 
been used by several clinical trials to evaluate the feasibility 
of PD-L1 expression as a predictive biomarker. Since testing 
for PD-L1 is not standardized, the evaluation of PD-L1 has 
several limitations. The cisplatin-pretreated arm (cohort 2) of 
the Imvigor 210 trial revealed an association between objec-
tive response rate (ORR) to atezolizumab and PD-L1 expres-
sion status (ORR was 27% in patients with PD-L1-positive 
immune cells  ≥ 5% vs 18% in those with PD-L1-positive 
immune cells  ≥ 1% vs 15% in all patients [81]. However, in the 
cisplatin-ineligible arm, the ORR was independent of PD-L1 
status [84]. Conversely, in the CheckMate 032 study, there was 
no difference in ORR between patients with PD-L1 expres-
sion  < 1% and those with PD-L1 expression  ≥ 1% (26.2% 
vs 24.0%, respectively) [87], CheckMate 275, evaluating 
nivolumab in metastatic urothelial carcinoma after platinum 
therapy, confirmed the association (ORR of 28.4, 23.8 and 
16.1% in patients with PD-L1 expression of 5% or greater, 
1% or greater and less than 1%, respectively) [82]. Finally, in 
KEYNOTE-045 trial, the benefit of pembrolizumab appeared 
to be independent of PD-L1 expression on tumor and infil-
trating immune cells [83]. Spatial, time and heterogeneity are 
limiting factors in PD-1 biomarkers [90].
Molecular subtypes of MIBC have recently been catego-
rized based on gene expression. The Cancer Genome Atlas 
(TCGA) [64] described four subtypes of BCa based on cluster 
analysis of messenger RNA (mRNA). The exploratory anal-
yses from cisplatin pretreated arm of the Imvigor 210 trial 
showed TCGA subtypes to be independently predictive for 
response to atezolizumab treatment [81]. Response to atezoli-
zumab occurred in all TCGA subtypes but was significantly 
higher in the luminal cluster II subtype than in other subtypes 
[81]. For cisplatin-ineligible patients, responses were seen 
across all subtypes and were more frequent with the luminal II 
subtype [84]. Conversely, in CheckMate 275, basal 1 subtype 
contained the highest proportion of responders [82].
High mutational load may be associated with better 
response to immunotherapy, particularly for checkpoint 
inhibitors, with some trials (such as Imvigor 210) showing 
a correlation between patients with a higher mutational bur-
den and better responses to immunotherapeutic agents [81]. 
Finally, gene expression profiling (such as Interferon y gene 
signature) and changes in tumor microenvironment (such 
as chemokines and CD8 + T-cell infiltration) are promising 
predictors of response to immunotherapy [81, 82].
Despite these promising findings, use of biomarkers to 
predict the response to systemic immunotherapy remains 
limited; indeed, a significant proportion of patients with neg-
ative biomarkers status still respond to treatment and many 
patients with positive biomarkers status fail to respond.
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Conclusions
Despite the plethora of studies investigating the role of uri-
nary, blood and tissue biomarkers in BCa with an ever-rising 
rate of data, none of the studies have reached the required 
level of evidence to change clinical practice and, therefore, 
none is widely used or to be recommended. Except for some 
specific clinical scenarios where biomarkers can be used as 
an adjunct in the clinical setting, use of biomarkers in BCa 
remains experimental and is still not recommended in clini-
cal practice. However, biomarkers are the basis for the indi-
vidualized medicine and represent undoubtedly the future 
of BCa treatment.
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